Enhancing immune cells to better fight tumors
Official title: Programming Metabolically Fit TILs for Immunotherapy
Funded at Lipo-Immuno Tech, LLC · NIH-10930154 · Data updated 2026-11-12
This study is looking at ways to make your immune cells, called tumor-infiltrating lymphocytes, even better at finding and fighting cancer by teaching them to recognize more cancer markers, which could help improve treatment results for people with different types of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lipo-Immuno Tech, LLC NIH-funded |
| Lab location | 1 site (Mount Pleasant, United States) |
| Project start | February 15, 2020 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R42CA239952-03 |
| Project ID | NIH-10930154 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with tumors that have multiple antigenic targets and who are seeking advanced immunotherapy options.
✕Less likely to help
Patients with tumors that do not express identifiable antigens or those who are not eligible for adoptive cell transfer may not benefit from this research.
What this research studies
This research focuses on improving the effectiveness of immune cells, specifically tumor-infiltrating lymphocytes (TILs), to target and destroy cancer cells. By genetically modifying these TILs to recognize multiple tumor antigens, the study aims to enhance their ability to control tumor growth when transferred back into patients. The approach involves using different growth factors to expand these modified TILs, potentially leading to better long-term outcomes for patients with various cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for cancer patients, improving their chances of recovery.
How similar studies have gone: Previous studies have shown promise in using modified TILs for cancer treatment, indicating that this approach has potential based on earlier successes.
Where this research is happening
-
Lipo-Immuno Tech, LLC
Mount Pleasant, United States Active
Researchers
- Principal investigator: Mehrotra, Shikhar — Lipo-Immuno Tech, LLC
- Study coordinator: Mehrotra, Shikhar
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.